Incyte (INCY) Depreciation & Amortization (CF) (2010 - 2026)
Incyte's (INCY) quarterly Depreciation & Amortization (CF) came in at $26.5 million in Q2 2026, up 15.52% YoY from $22.9 million in Q2 2025, and up 11.23% on a QoQ basis from $23.8 million in Q1 2026.
Analysis
Incyte (INCY) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $26.5 million in Q2 2026.
- Quarterly Depreciation & Amortization (CF) rose 15.52% year-over-year to $26.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $98.3 million (up 8.56% YoY) and the FY2025 annual result came in at $93.3 million, up 4.52% from the prior year.
- Depreciation & Amortization (CF) grew to $26.5 million in Q2 2026, from $23.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $26.5 million in Q2 2026 to a low of $16.4 million in Q1 2022.
- A 5-year average of $21.3 million and a median of $22.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 28.15% — and 2025, when it advanced 1.89%.
- Tracing INCY's Depreciation & Amortization (CF) over 5 years: stood at $18.2 million in 2022, then gained by 19.45% to $21.8 million in 2023, then rose by 4.46% to $22.7 million in 2024, then grew by 5.49% to $24.0 million in 2025, then increased by 10.4% to $26.5 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $26.5 million (Q2 2026), $23.8 million (Q1 2026), and $24.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 26.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.48 Mn |
| Mar 31, 2026 | 23.80 Mn |
| Dec 31, 2025 | 23.98 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 22.92 Mn |
| Mar 31, 2025 | 22.36 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Sep 30, 2024 | 22.52 Mn |
| Jun 30, 2024 | 22.05 Mn |
| Mar 31, 2024 | 21.95 Mn |
| Dec 31, 2023 | 21.76 Mn |
| Sep 30, 2023 | 21.39 Mn |
| Jun 30, 2023 | 20.30 Mn |
| Mar 31, 2023 | 19.21 Mn |
| Dec 31, 2022 | 18.22 Mn |
| Sep 30, 2022 | 16.69 Mn |
| Jun 30, 2022 | 16.51 Mn |
| Mar 31, 2022 | 16.44 Mn |
| Dec 31, 2021 | 14.86 Mn |
| Sep 30, 2021 | 14.69 Mn |